Evidence map›Paper›PMID 27721664›Full record

ArticleClinical Medicine Insights. Oncology2016

Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?

Nader I Al-Dewik, Hisham M Morsi, Muthanna M Samara, Rola S Ghasoub, Cinquea C Gnanam, Subi K Bhaskaran, Abdulqadir J Nashwan, Rana M Al-Jurf, Mohamed A Ismail, Mohammed M AlSharshani and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Nader I Al-DewikQatar Medical Genetics Center, Hamad General Hospital (HGH), Hamad Medical Corporation, Doha, Qatar.; National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.; Interim Translational Research Institute (iTRI), Hamad Medical Corporation, Doha, Qatar.; Faculty of Health and Social Care Sciences, Kingston University and St. George's University of London, London, UK.
Hisham M MorsiFaculty of Health and Social Care Sciences, Kingston University and St. George's University of London, London, UK.; Academic Health System, Hamad Medical Corporation, Doha, Qatar.; Quality of Life Unit, Hamad Medical Corporation, Doha, Qatar.
Muthanna M SamaraDepartment of Psychology, Kingston University, London, UK.
Rola S GhasoubNational Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
Cinquea C GnanamNational Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
Subi K BhaskaranNational Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
Abdulqadir J NashwanNational Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
Rana M Al-JurfInterim Translational Research Institute (iTRI), Hamad Medical Corporation, Doha, Qatar.
Mohamed A IsmailInterim Translational Research Institute (iTRI), Hamad Medical Corporation, Doha, Qatar.
Mohammed M AlSharshaniMolecular Genetics Laboratory, Hamad Medical Corporation, Doha, Qatar.
Ali A AlSayabInterim Translational Research Institute (iTRI), Hamad Medical Corporation, Doha, Qatar.; Primary Health Care Center (PHCC), Hamad Medical Corporation, Doha, Qatar.
Tawfeg I Ben-OmranQatar Medical Genetics Center, Hamad General Hospital (HGH), Hamad Medical Corporation, Doha, Qatar.
Rani B KhatibMedicines Management and Pharmacy Services, Leeds Teaching Hospitals, NHS Trust, Leeds, UK.; Faculty of Medicines and Health, LICAMM, University of Leeds, Leeds, UK.
Mohamed A YassinNational Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
Hamad Medical Corporation · QANational Center for Cancer Care and Research · QASt George's, University of London · GBKingston University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), for treating chronic myeloid leukemia (CML), a substantial proportion of patients' treatments fail.

aimThis study investigates the correlation between patient adherence and failure of TKIs' treatment in a follow-up study.

methodsThis is a follow-up study of a new cohort of CML patients. Adherence to IM is assessed using the Medication Event Monitoring System (MEMS 6 TrackCap, AARDEX Ltd). The 9-item Morisky Medication Adherence Scale, medication possession ratio (MPR) calculation, and the electronic medical records are used for identifying potential factors that influence adherence. Clinical outcomes are assessed according to the European Leukemia Net 2013 guidelines via reverse transcriptase quantitative polymerase chain reaction measurement of the level of

resultsA total of 36 CML patients (5 citizens and 31 noncitizen residents) consented to participate in the study. The overall mean MEMS score was 89. Of the 36 patients, 22 (61%) were classified as adherent (mean: 95) and 14 (39%) were classified as nonadherent (mean: 80.2). Adherent patients were significantly more likely to obtain optimal response (95%) compared to the nonadherent group (14.3%; DISCUSSION AND

conclusionThis is the first prospective study to evaluate CML patients' adherence and response to IM in Qatar. The high rate of treatment failure observed in Qatar is explained by poor adherence. An economic factor (unaffordable drug prices) is one of the main causes of nonadherence and efforts should be made locally to improve access to medication for cancer diseases. Other risk factors associated with poor adherence could be improved by close monitoring and dose adjustment. Monitoring risk factors for poor adherence and patient education that include direct communication between the health-care teams, doctors, nurses, pharmacists, and patients are essential components for maximizing the benefits of TKI therapy and could rectify this problem. The preliminary results show that patients' response to treatment may be directly linked to patients' adherence to treatment. However, further in-depth and specific analysis may be necessary in a larger cohort.

Indexed as

9-item Morisky Medication Adherence ScaleABL1adherenceBCR-ABL1 mutationschronic myeloid leukemiaimatinib mesylateMedication Event Monitoring Systemmedication possession ratioreverse transcriptase quantitative polymerase chain reactiontreatment response BCR-ABL1

Identifiers

PMID27721664
PMCPMC5047706
OpenAlexW2527511469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.